303 related articles for article (PubMed ID: 19736617)
1. The importance of target validation in drug discovery and development.
Lowe JA; Jones P; Wilson DM
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):581-4. PubMed ID: 19736617
[No Abstract] [Full Text] [Related]
2. Challenges in the search for drugs to treat central nervous system disorders.
Enna SJ; Williams M
J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
[TBL] [Abstract][Full Text] [Related]
3. Correct assessment of new compounds using in vivo screening models can reduce false positives.
Bueters TJ; Hoogstraate J; Visser SA
Drug Discov Today; 2009 Jan; 14(1-2):89-94. PubMed ID: 18840543
[TBL] [Abstract][Full Text] [Related]
4. siRNAs in drug discovery: target validation and beyond.
Natt F
Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
[TBL] [Abstract][Full Text] [Related]
5. [Drug-induced long QT syndrome].
Kishida H
Nihon Rinsho; 2007 Oct; 65 Suppl 8():426-9. PubMed ID: 18074575
[No Abstract] [Full Text] [Related]
6. Pharmacological MRI: a biomarker in CNS drug discovery and development?
Lucignani G; Bastianello S
Funct Neurol; 2007; 22(2):71-3. PubMed ID: 17637208
[No Abstract] [Full Text] [Related]
7. [Drug-induced sexual and gonadal disorders].
Katabami T; Iwamoto T
Nihon Rinsho; 2006 Jun; Suppl 2():321-5. PubMed ID: 16817413
[No Abstract] [Full Text] [Related]
8. RNA interference screening for the discovery of oncology targets.
Quon K; Kassner PD
Expert Opin Ther Targets; 2009 Sep; 13(9):1027-35. PubMed ID: 19650760
[TBL] [Abstract][Full Text] [Related]
9. Smaller is better for antibiotic discovery.
Waldrop GL
ACS Chem Biol; 2009 Jun; 4(6):397-9. PubMed ID: 19537754
[TBL] [Abstract][Full Text] [Related]
10. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting?
Dyson A; Singer M
Crit Care Med; 2009 Jan; 37(1 Suppl):S30-7. PubMed ID: 19104223
[TBL] [Abstract][Full Text] [Related]
11. Opportunities and challenges in the discovery of new central nervous system drugs.
Krause JE; Chenard BL
Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
[TBL] [Abstract][Full Text] [Related]
12. Medication effects on metabolic rate: a systematic review (part 2).
Dickerson RN; Roth-Yousey L
J Am Diet Assoc; 2005 Jun; 105(6):1002-9. PubMed ID: 15942556
[No Abstract] [Full Text] [Related]
13. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
Wacker DA; Miller KJ
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
[TBL] [Abstract][Full Text] [Related]
14. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
Brunner D; Balcı F; Ludvig EA
Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
[TBL] [Abstract][Full Text] [Related]
15. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective.
Singh M; Johnson L
Clin Cancer Res; 2006 Sep; 12(18):5312-28. PubMed ID: 17000664
[TBL] [Abstract][Full Text] [Related]
16. Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents.
Tian X; Switzer AG; Derose SA; Mishra RK; Solinsky MG; Mumin RN; Ebetino FH; Jayasinghe LR; Webster ME; Colson AO; Crossdoersen D; Pinney BB; Farmer JA; Dowty ME; Obringer CM; Cruze CA; Burklow ML; Suchanek PM; Dong L; Dirr MK; Sheldon RJ; Wos JA
J Med Chem; 2008 Oct; 51(19):6055-66. PubMed ID: 18771254
[TBL] [Abstract][Full Text] [Related]
17. In vivo target validation using gene invalidation, RNA interference and protein functional knockout models: it is the time to combine.
Vidalin O; Muslmani M; Estienne C; Echchakir H; Abina AM
Curr Opin Pharmacol; 2009 Oct; 9(5):669-76. PubMed ID: 19646923
[TBL] [Abstract][Full Text] [Related]
18. Quality by design in lead optimization: a new strategy to address productivity in drug discovery.
Rossi T; Braggio S
Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263
[TBL] [Abstract][Full Text] [Related]
19. Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.
Elangbam CS
Vet Pathol; 2009 Jan; 46(1):10-24. PubMed ID: 19112110
[TBL] [Abstract][Full Text] [Related]
20. Experimental biology 2006: advancing the biomedical frontier.
Edwards C
IDrugs; 2006 Jun; 9(6):402-4. PubMed ID: 16752307
[No Abstract] [Full Text] [Related]
[Next] [New Search]
